Literature DB >> 20216240

Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.

Noël E C Schartz1, Cécile Farges, Isabelle Madelaine, Heriberto Bruzzoni, Fabien Calvo, Axel Hoos, Céleste Lebbé.   

Abstract

Anecdotal cases of partial or complete responses have been reported after ipilimumab therapy for stage IV melanoma with brain metastasis treated earlier by surgery or radiosurgery. We report the first case of ipilimumab monotherapy resulting in durable complete remission of untreated, progressive brain metastases in a patient with stage IV melanoma. This case and earlier reports provide support for the further evaluation of ipilimumab in melanoma patients with brain metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20216240     DOI: 10.1097/CMR.0b013e3283364a37

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  25 in total

1.  Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab.

Authors:  I Bot; C U Blank; D Brandsma
Journal:  J Neurol       Date:  2012-04-18       Impact factor: 4.849

Review 2.  Brain metastasis: new opportunities to tackle therapeutic resistance.

Authors:  Joan Seoane; Leticia De Mattos-Arruda
Journal:  Mol Oncol       Date:  2014-06-02       Impact factor: 6.603

Review 3.  Immunomodulatory therapy for melanoma: ipilimumab and beyond.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Clin Dermatol       Date:  2013 Mar-Apr       Impact factor: 3.541

Review 4.  Current challenges in designing GBM trials for immunotherapy.

Authors:  Shiao-Pei Weathers; Mark R Gilbert
Journal:  J Neurooncol       Date:  2015-01-11       Impact factor: 4.130

5.  Immune checkpoint inhibition in patients with brain metastases.

Authors:  Tanner Johanns; Saiama N Waqar; Daniel Morgensztern
Journal:  Ann Transl Med       Date:  2016-10

6.  Clinical trial design in brain metastasis: approaches for a unique patient population.

Authors:  David M Peereboom
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

7.  Melanoma brain metastases: is it time to reassess the bias?

Authors:  Jaclyn C Flanigan; Lucia B Jilaveanu; Mark Faries; Mario Sznol; Stephan Ariyan; James B Yu; Jonathan P S Knisely; Veronica L Chiang; Harriet M Kluger
Journal:  Curr Probl Cancer       Date:  2011 Jul-Aug       Impact factor: 3.187

Review 8.  Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.

Authors:  Keiran S M Smalley; Inna V Fedorenko; Rajappa S Kenchappa; Solmaz Sahebjam; Peter A Forsyth
Journal:  Int J Cancer       Date:  2016-04-30       Impact factor: 7.396

Review 9.  Treating recurrent glioblastoma: an update.

Authors:  Carlos Kamiya-Matsuoka; Mark R Gilbert
Journal:  CNS Oncol       Date:  2015

Review 10.  Systemic therapy of brain metastases.

Authors:  Harry C Brastianos; Daniel P Cahill; Priscilla K Brastianos
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.